Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,007 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J. Zhou C, et al. Among authors: ding y. J Am Acad Dermatol. 2023 Nov;89(5):911-919. doi: 10.1016/j.jaad.2023.02.063. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019385 Clinical Trial.
Comparison of different incremental dose regimens of narrow-band ultraviolet B in skin types III to V: A prospective, randomized, single-blind, parallel study in patients with psoriasis.
Yu Y, Yi X, Zhang Y, Yu N, Yu Q, Le Q, Chen Z, Ding Y, Shi Y. Yu Y, et al. Among authors: ding y. J Am Acad Dermatol. 2021 Apr;84(4):1136-1138. doi: 10.1016/j.jaad.2020.06.993. Epub 2020 Jun 30. J Am Acad Dermatol. 2021. PMID: 32619612 Clinical Trial. No abstract available.
Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial.
Liu L, Zhang C, Wang J, Chen K, Ding Y, Yan G, Lu Q, Li W, Fang H, Cheng H, Zhang J, He Y, Zhu W, Lu Y, Huang J, Pan W, Li M, Cao S, Li S, Han X, He L, Chen Y, Zheng M. Liu L, et al. Among authors: ding y. Eur J Dermatol. 2020 Oct 1;30(5):580-590. doi: 10.1684/ejd.2020.3876. Eur J Dermatol. 2020. PMID: 33052103 Clinical Trial.
Visit Adherence of Mild to Moderate Psoriasis Patients: A Mobile-Based Randomized Study.
Zhao Y, Wang G, Ni W, Song Z, Chen K, Zhang C, Zhang S, Ding Y, Zheng M, Shi Y, Lin Z, Liu X, Zhang X, Zhou Q, Ahmed KD. Zhao Y, et al. Among authors: ding y. Patient Prefer Adherence. 2021 Jan 5;14:2551-2557. doi: 10.2147/PPA.S277103. eCollection 2020. Patient Prefer Adherence. 2021. PMID: 33447016 Free PMC article.
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, Goh AH, Liu R, Zhang Z, Zhang J. Zhao Y, et al. Among authors: ding y. Am J Clin Dermatol. 2021 Nov;22(6):877-889. doi: 10.1007/s40257-021-00627-2. Epub 2021 Aug 9. Am J Clin Dermatol. 2021. PMID: 34374027 Free PMC article. Clinical Trial.
Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J. Cai L, et al. Among authors: ding y. Adv Ther. 2022 Jan;39(1):583-597. doi: 10.1007/s12325-021-01899-0. Epub 2021 Nov 23. Adv Ther. 2022. PMID: 34816373 Free PMC article. Clinical Trial.
Randomized, Placebo-Controlled, Multicenter Clinical Study on the Efficacy and Safety of Lidocaine Patches in Chinese Patients with Postherpetic Neuralgia.
Wang A, Li H, Xie Z, Li L, Jiang X, Guo Q, Hu F, Zhang J, Cui Y, Ding Y, Fang H, Han X, Guo S, Wang J, Ni N. Wang A, et al. Among authors: ding y. Dermatol Ther (Heidelb). 2023 Jul;13(7):1477-1487. doi: 10.1007/s13555-023-00938-8. Epub 2023 Jun 2. Dermatol Ther (Heidelb). 2023. PMID: 37268784 Free PMC article.
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.
Zhao Y, Zhang J, Yang B, Li J, Ding Y, Wu L, Zhang L, Wang J, Zhu X, Zhang F, Tao X, Li Y, Zhang C, Li L, Lu J, Diao Q, Lu Q, Man X, Li F, Xia X, Cheng H, Jia Y, Zhao G, Yan J, Chen B. Zhao Y, et al. Among authors: ding y. Chin Med J (Engl). 2024 Jan 20;137(2):200-208. doi: 10.1097/CM9.0000000000002747. Epub 2023 Jul 21. Chin Med J (Engl). 2024. PMID: 37482623 Free PMC article. Clinical Trial.
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J. Cai L, et al. Among authors: ding y. Br J Dermatol. 2024 Feb 15:ljae062. doi: 10.1093/bjd/ljae062. Online ahead of print. Br J Dermatol. 2024. PMID: 38366639
20,007 results
You have reached the last available page of results. Please see the User Guide for more information.